Targeting EIF4A Triggers an Interferon Response to Synergize With Chemotherapy and Suppress Triple-Negative Breast Cancer

Scientists showed that therapeutically targeting the RNA helicase eIF4A by Zotatifin exerted pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic TNBC mouse models.